These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 16620443)
21. Digestive Disease Week 2000 conference report: New treatments for chronic hepatitis C. Brown PJ; Neuman MG Can J Clin Pharmacol; 2001; 8(2):67-71. PubMed ID: 11493933 [TBL] [Abstract][Full Text] [Related]
22. Successful treatment with peginterferon and ribavirin in a patient with acute hepatitis C evolving into chronicity. Hsieh TH; Kao JH; Lai MY; Chen PJ; Chen DS J Formos Med Assoc; 2005 May; 104(5):354-8. PubMed ID: 15959603 [TBL] [Abstract][Full Text] [Related]
23. [Adverse effects of combining polyethylene glycol interferon with ribavilin on hepatitis C patients]. Si CW Zhonghua Gan Zang Bing Za Zhi; 2003 Nov; 11(11):686-7. PubMed ID: 14636449 [No Abstract] [Full Text] [Related]
24. Second thoughts about secondary analyses. Ferenci P Dig Liver Dis; 2005 Oct; 37(10):805-7; author reply 808-9. PubMed ID: 16023903 [No Abstract] [Full Text] [Related]
25. HCV infection in the setting of HIV: prevalence, disease, treatment. Laurence J AIDS Read; 2006 Mar; 16(3):115-6. PubMed ID: 16538952 [No Abstract] [Full Text] [Related]
26. Hepatitis C: Enhancing treatment for hepatitis C among drug users. Grebely J; Dore GJ Nat Rev Gastroenterol Hepatol; 2011 Jan; 8(1):11-3. PubMed ID: 21119610 [No Abstract] [Full Text] [Related]
28. Seventy-two weeks of peginterferon and ribavirin for patients with partial early virologic response? Hoefs JC; Morgan TR Hepatology; 2007 Dec; 46(6):1671-4. PubMed ID: 18046713 [No Abstract] [Full Text] [Related]
29. [Drug therapy of hepatitis B and C]. Färkkilä M Duodecim; 2003; 119(6):519-29. PubMed ID: 12708339 [No Abstract] [Full Text] [Related]
30. PegIFN/ribavirin during acute HCV coinfection. Bernard EJ IAPAC Mon; 2004 Jul; 10(7):260-1. PubMed ID: 15624247 [No Abstract] [Full Text] [Related]
31. Predictors of response of U.S. veterans to treatment for the hepatitis C virus. Riley TR Hepatology; 2008 Jan; 47(1):356; author reply 356-7. PubMed ID: 18161713 [No Abstract] [Full Text] [Related]
32. [PEG-interferons: significance for the treatment of viral hepatitis B and C]. Wedemeyer H; Cornberg M; Manns MP Dtsch Med Wochenschr; 2001 Jun; 126 Suppl 1():S68-75. PubMed ID: 11450618 [No Abstract] [Full Text] [Related]
33. Delaying HCV treatment in HIV-positive patients. Carter M IAPAC Mon; 2005 May; 11(5):147. PubMed ID: 16201045 [No Abstract] [Full Text] [Related]
34. [Treatment of chronic hepatitis C with pegylated alpha-interferons]. Niederau C Dtsch Med Wochenschr; 2002 Mar; 127(11):563-6. PubMed ID: 11894177 [No Abstract] [Full Text] [Related]
35. Hepatitis drug gets approval for coinfection treatment. AIDS Patient Care STDS; 2005 May; 19(5):351. PubMed ID: 15916498 [No Abstract] [Full Text] [Related]
36. FDA approves Pegasys and Copegus for hepatitis C in patients with HIV co-infection. Bartlett JG Hopkins HIV Rep; 2005 May; 17(3):15. PubMed ID: 16419314 [No Abstract] [Full Text] [Related]
37. [Comparison of hepatitis C viral RNA and core antigen kinetics in the therapeutic follow up of hepatitis C virus and human immunodeficiency virus co-infected patients, treated by bitherapy interferon-ribavirin, within the framework of RIBAVIC protocol]. Pivert A; Payan C; Lunel F; Pathol Biol (Paris); 2004 Nov; 52(9):522-8. PubMed ID: 15531116 [TBL] [Abstract][Full Text] [Related]